Search

Your search keyword '"Amgen Inc. -- Planning"' showing total 51 results
Start Over Descriptor "Amgen Inc. -- Planning"
51 results on '"Amgen Inc. -- Planning"'

1. Biotech Center.

Author

Welk, Hannah K.

Subjects
Biotechnology, Biotechnology industry -- Planning, Shopping centers -- Planning, Amgen Inc. -- Planning, Company business planning
Abstract

The Los Angeles Bioscience Ecosystem Summit Twenty 24 was held last month at UCLA. Speakers at the event included Robert Bradway, the chief executive of Thousand Oaks-based Amgen Inc.; Arie [...]

Published
2024

2. THE WEEK

Subjects
International Business Machines Corp. -- Planning, Amgen Inc. -- Planning, Cooper Tire & Rubber Co. -- Planning, Patients -- Care and treatment, Biotechnology industry -- Planning, Tire industry -- Planning, Computer industry -- Planning, Company business planning, Microcomputer industry, Computer industry, Business, Business, regional
Abstract

THIS COMPUTES: Cleveland Clinic and IBM announced a 10-year partnership to establish a joint center, dubbed the Discovery Accelerator, to advance the pace of discovery in health care and life [...]

Published
2021

3. A Time for Growth

Author

Hemp, Paul

Subjects
Amgen Inc. -- Officials and employees, Amgen Inc. -- Planning, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Planning, Company business planning, Business, Business, general
Abstract

Amgen CEO Kevin Sharer discusses growth strategies he has launched, focusing on the role of corporate culture as a primary factor in successful implementation.

Published
2004

4. Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today's Virtual Investor & Analyst Day

Subjects
Cytokinetics Inc. -- Planning, Amgen Inc. -- Planning, Pipelines, Biotechnology industries -- Planning, Commercial buildings -- Planning, Myosin, Cardiovascular diseases, Muscle proteins, Company business planning, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Jul 15, 2020 (GLOBE NEWSWIRE via COMTEX) -- Topline Results from GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4 Licensing Collaboration [...]

Published
2020

5. Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones

Subjects
Astellas Pharma Inc. -- Planning, Cytokinetics Inc. -- Planning, Amgen Inc. -- Planning, Biotechnology industries -- Planning, Myosin, Pharmaceutical industry -- Planning, Muscle proteins, Company business planning, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Calif., Jan 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor [...]

Published
2020

6. Maker Deeply Cuts Price Of Steep Cholesterol Drug

Author

Thomas, Katie

Subjects
Amgen Inc. -- Planning, Anticholesteremic agents -- Prices and rates, Biotechnology industries -- Planning, Company business planning, Company pricing policy, General interest, News, opinion and commentary
Abstract

For years, the drug maker Amgen has struggled to sell its new anti-cholesterol drug, Repatha after insurers balked over the list price of about $14,000 a year. On Wednesday, Amgen [...]

Published
2018

7. LATEST COMPANY NEWS

Subjects
United States. Food and Drug Administration -- Planning, United States. Internal Revenue Service -- Planning, Allergan PLC -- Planning, Amgen Inc. -- Planning, Bristol-Myers Squibb Co. -- Planning, Pfizer Inc. -- Planning, AbbVie Inc. -- Planning, AstraZeneca PLC -- Planning, Array BioPharma Inc. -- Planning, Bain Capital L.L.C. -- Planning, Hospira Inc. -- Planning, Celgene Corp. -- Planning, Allergan Inc. (Irvine, California) -- Planning, Mylan Pharmaceuticals Inc. -- Planning, Novartis AG -- Planning, GlaxoSmithKline PLC -- Planning, Ono Pharmaceutical Company Ltd. -- Planning, Medical care, Cost of, Antineoplastic agents -- Planning, Type 2 diabetes, Antimitotic agents -- Planning, Company business planning, Business, international, European Union -- Planning, European Union. European Commission -- Planning, Jardiance (Medication), Basaglar (Medication), Farxiga (Medication), Yervoy (Medication), Ibrance (Medication), Zejula (Medication), Emgality (Medication), Tivicay (Medication), Fasenra (Medication), Faslodex (Medication), Calquence (Medication), Opdivo (Medication), Crestor (Medication), Trelegy Ellipta (Medication), Epanova (Medication), Juluca (Medication), Braftovi (Medication), Symbicort (Medication), Lynparza (Medication), Tagrisso (Medication), Brilinta (Medication), Enhertu (Medication), Trulicity (Medication), Nucala (Medication), Benlysta (Medication), Vyndaqel (Medication), Dovato (Medication), Taltz (Medication), Nexium 24HR (Medication), Advair Diskus (Medication), Exparel (Medication), Imfinzi (Medication), Breo Ellipta (Medication)
Abstract

News and Commentary FiercePharma - Stada aids GSK's consumer health spinoff plan with deal for 15 products - 24/2/2020 GlaxoSmithKline's looking to sell some non-core over-the-counter products to help cover [...]

Published
2020

8. Amgen adjusts growth plans to other areas: biotech giant finds little room to expand locally

Author

Coates, Chris

Subjects
Amgen Inc. -- Location, Amgen Inc. -- Human resource management, Amgen Inc. -- Planning, Pharmaceutical industry -- Location, Pharmaceutical industry -- Human resource management, Pharmaceutical industry -- Planning, Company personnel management, Company business planning, Business, Business, regional
Abstract

Gary Wartik, economic development manager for Thousand Oaks, isn't worried about plans by his city's largest employer to relocate workers to Colorado. After all, officials with Amgen, the world's biggest [...]

Published
2006

9. Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day

Subjects
United States. Food and Drug Administration -- Planning, Astellas Pharma Inc. -- Planning, Cytokinetics Inc. -- Planning, Amgen Inc. -- Planning, Clinical trials, Troponin, Biotechnology industries -- Planning, Medical research, Myosin, Pharmaceutical industry -- Planning, Company business planning, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Calif., Oct 16, 2018 (GLOBE NEWSWIRE via COMTEX) -- Investigational New Drug Applications Recently Filed for Two New Cardiac Programs: Cardiac Troponin Activator and Cardiac Myosin Inhibitor [...]

Published
2018

10. Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

Subjects
Amgen Inc. -- Planning, Professional baseball, Biotechnology industries -- Planning, Multiple myeloma -- Care and treatment, Company business planning, General interest, News, opinion and commentary, Major League Baseball -- Planning
Abstract

United States: AMGEN INC. has issued the following press release: Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create [...]

Published
2018

11. Coherus resubmits BLA for Neulasta biosimilar

Subjects
Amgen Inc. -- Planning, Biotechnology industries -- Planning, Company business planning, Business, Business, international, Neulasta (Medication)
Abstract

M2 PRESSWIRE-May 4, 2018-: Coherus resubmits BLA for Neulasta biosimilar (C)1994-2018 M2 COMMUNICATIONS RDATE:03052018 Coherus BioSciences Inc. (NASDAQ:CHRS) gained $2.20 (17%) to $14.90 on Thursday after resubmitting a BLA for [...]

Published
2018

12. Regeneron Takes Aim at Amgen and Esperion Therapeutics

Subjects
Amgen Inc. -- Planning, Regeneron Pharmaceuticals Inc. -- Planning, Sanofi S.A. -- Planning, Anticholesteremic agents -- Planning, Patient compliance, Biotechnology industries -- Planning, Cholesterol, Pharmaceutical industry -- Planning, Company business planning, Business, international, Repatha (Medication), Praluent (Medication)
Abstract

Almost one year after competitor Amgen, Inc. (NASDAQ:AMGN) reported that its cholesterol-lowering drug, Repatha, reduced the risk of major adverse cardiac events (MACE), Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NYSE:SNY) unveiled [...]

Published
2018

13. Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in Exchange for Wider Coverage

Subjects
Amgen Inc. -- Planning, Regeneron Pharmaceuticals Inc. -- Planning, E*TRADE Financial Corp. -- Planning, Sanofi S.A. -- Planning, Securities industry -- Planning, Anticholesteremic agents -- Planning, Biotechnology industries -- Planning, Cholesterol, Pharmaceutical industry -- Planning, Cardiovascular agents -- Planning, Securities industry, Company business planning, General interest, News, opinion and commentary, Praluent (Medication)
Abstract

New York City: E*TRADE Financial Corporation (ETFC) has issued the following press release: The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange [...]

Published
2018

14. AliveGen Inc. in Thousand Oaks has sold its drug candidates to Biogen Inc. in a deal valued at up to $562 million

Author

Varian, Ethan

Subjects
Biogen Inc. -- Planning, Amgen Inc. -- Planning, Biotechnology industries -- Planning, Biological products industry -- Planning, Company business planning, Business, Business, regional
Abstract

AliveGen Inc. in Thousand Oaks has sold its drug candidates to Biogen Inc. in a deal valued at up to $562 million. The portfolio of the fledgling biotech startup, founded [...]

Published
2018

15. Amgen Plans 'Next Generation' Production Plant: Facility in Rhode Island will use less water and energy

Author

Floersh, Helen

Subjects
United States. Food and Drug Administration -- Planning, Amgen Inc. -- Planning, Biotechnology industries -- Planning, Leukemia, Drug approval, Pharmaceutical industry -- Planning, Company business planning, Business, Business, regional, European Union. European Commission -- Planning, Xgeva (Medication)
Abstract

The past month has been a busy one for Amgen Inc. The Thousand Oaks-based biopharmaceutical firm announced the opening of a 'next generation' drug manufacturing plant in Rhode Island, saw [...]

Published
2018

16. Amgen Inc

Author

Bedolla, Stephanie

Subjects
Amgen Inc. -- Planning, Tax returns, Biotechnology industries -- Planning, Tax reform, Company business planning, Business, Business, regional
Abstract

Amgen Inc. expects to pay between $6 billion and $6.5 billion in taxes as it repatriates money from overseas operations, the company said in a filing with the Securities and [...]

Published
2018

17. Sanofi Investors Have Worst Day in Six Months

Subjects
Amgen Inc. -- Planning, Regeneron Pharmaceuticals Inc. -- Planning, Sanofi S.A. -- Planning, Anticholesteremic agents -- Planning, Biotechnology industries -- Planning, Pharmaceutical industry -- Planning, Patent law, Company business planning, Business, Repatha (Medication), Praluent (Medication)
Abstract

Byline: Kate Norton To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: https://www.thestreet.com/story/13944821/1/sanofi-shares-tumble-after-u-s-ruling-on-praulent-drugs-sales.html Sanofi SA (SNY) led Frances's benchmark CAC-40 lower Friday after [...]

Published
2017

18. Former Major League Baseball MLB All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma

Subjects
Amgen Inc. -- Planning, Professional baseball, Biotechnology industries -- Planning, Multiple myeloma -- Care and treatment, Company business planning, Biotechnology industry, Biological sciences, Business, Major League Baseball -- Planning
Abstract

2018 JUL 30 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Amgen (NASDAQ:AMGN) announced the launch of Myeloma MVPTM, a national campaign to help those [...]

Published
2018

19. Q1 2012 Amgen Earnings Conference Call - Final

Subjects
Amgen Inc. -- Planning, Biotechnology industry -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Prolia (Medication), Enbrel (Medication), Epogen (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

Presentation OPERATOR: My name is Marvin, and I will be your conference facilitator today for Amgen's first-quarter earnings conference call. All lines have been placed on mute to prevent any [...]

Published
2012

20. Event Brief of Q4 2011 Amgen Inc Earnings Conference Call and to Discuss Acquisition of Micromet - Final

Subjects
Amgen Inc. -- Planning, Biotechnology industry -- Planning, Hypercholesterolemia, Company business planning, Business, Aranesp (Medication), Prolia (Medication), Sensipar (Medication), Enbrel (Medication), Epogen (Medication), Xgeva (Medication), Neulasta (Medication), Nplate (Medication), Vectibix (Medication)
Abstract

PARTICIPANTS . Arvind Sood, Amgen Inc, VP, IR . Kevin Sharer, Amgen Inc, Chairman, CEO . Robert Bradway, Amgen Inc, President, COO . Jon Peacock, Amgen Inc, CFO . Tony [...]

Published
2012

21. Q4 2011 Amgen Inc Earnings Conference Call and to Discuss Acquisition of Micromet - Final

Subjects
Amgen Inc. -- Planning, Biotechnology industry -- Planning, Hypercholesterolemia, Company business planning, Business, Aranesp (Medication), Prolia (Medication), Sensipar (Medication), Enbrel (Medication), Epogen (Medication), Xgeva (Medication), Neulasta (Medication), Nplate (Medication), Vectibix (Medication)
Abstract

Presentation OPERATOR: My name is Marvin, and I will be your conference facilitator today for Amgen's fourth-quarter and full-year 2011 financial results conference call. All lines have been placed on [...]

Published
2012

22. United States : AMGEN plans to purchase 100% of Catherex

Subjects
Amgen Inc. -- Planning, Biotechnology industries -- Planning, Company business planning, Business, international, Imlygic (Medication)
Abstract

Amgen Inc is seeking to buy 100% of Catherex, Inc., USA, a spin-off of Medigene. Medigene USA is entitled to approximately 40% of payments to be made by Amgen. Medigene [...]

Published
2015

23. Q3 2011 Amgen Inc Earnings Conference Call - Final

Subjects
Amgen Inc. -- Planning, Financial markets, Biotechnology industry -- Planning, Stomach cancer, Pharmaceutical industry -- Planning, Company business planning, Business, Prolia (Medication), Enbrel (Medication), Epogen (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

Presentation OPERATOR: My name is Marvin and I will be your conference facilitator today for Amgen's third-quarter earnings conference call. All lines have been placed on mute to prevent any [...]

Published
2011

24. Q2 2011 Amgen Inc Earnings Conference Call - Final

Subjects
Amgen Inc. -- Planning, Financial markets, Corporations, Biotechnology industry -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Prolia (Medication), Enbrel (Medication), Epogen (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

Presentation OPERATOR: My name is Dennis, and I will be your conference facilitator today for Amgen's second quarter earnings conference call. All lines have been placed on mute to prevent [...]

Published
2011

25. Event Brief of Q2 2011 Amgen Inc Earnings Conference Call - Final

Subjects
Amgen Inc. -- Planning, Financial markets, Corporations, Biotechnology industry -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Prolia (Medication), Enbrel (Medication), Epogen (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

PARTICIPANTS . Arvind Sood, Amgen Inc, VP, IR . Kevin Sharer, Amgen Inc, Chairman of the Board, CEO and President . Jonathan Peacock, Amgen Inc, CFO . Bob Bradway, Amgen [...]

Published
2011

26. Q2 2011 Amgen Inc Earnings Conference Call - Final

Subjects
Amgen Inc. -- Planning, Financial markets, Corporations, Biotechnology industry -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Prolia (Medication), Enbrel (Medication), Epogen (Medication), Xgeva (Medication), Neulasta (Medication)
Abstract

Presentation OPERATOR: My name is Dennis, and I will be your conference facilitator today for Amgen's second quarter earnings conference call. All lines have been placed on mute to prevent [...]

Published
2011

27. Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans

Subjects
United States. Food and Drug Administration -- Planning, Amgen Inc. -- Planning, Biotechnology industry -- Planning, Company business planning, Business, News, opinion and commentary
Abstract

Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018 Guides to Improved Adjusted Operating Margin of 52-54 Percent by 2018 Reinitiating Share Repurchases [...]

Published
2014

28. Bio-giant Amgen to go on building, hiring spree

Author

Dineen, J.K.

Subjects
Amgen Inc. -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Business, regional
Abstract

World's largest bio technology company Amgen is planning to expand its add 500,000 square feet research and development space to its San Francisco operations. The company will also increase its head count by 220 by the end of this fiscal year.

Published
2006

29. Amgen cancels plans for Irish plant

Subjects
Amgen Inc. -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, General interest, Business, regional
Abstract

Byline: Allison Bruce Oct. 4--An Irish manufacturing center that would have produced existing and future drugs for Amgen Inc. in Europe has been scratched as the company works to trim [...]

Published
2007

30. Giant Amgen scopes area

Author

Jones, Amanda

Subjects
Research Triangle Park, North Carolina -- Buildings and facilities, Amgen Inc. -- Planning, Biological products industry -- Buildings and facilities, Biotechnology industry -- Planning, Business, Business, regional
Abstract

Amgen Inc. is looking for a biological manufacturing site and has inquired about Research Triangle Park, North Carolina locations. Amgen is planning to create 300 job positions and spend $500 million.

Published
2002

31. EPO market shaken by CMS' plans to cut reimbursements

Author

Osborne, Randall

Subjects
Amgen Inc. -- Planning, Pharmaceutical industry -- Planning, Cytokines -- Planning, Medicare -- Planning, Cancer -- Care and treatment, Glycoproteins, Erythropoietin, Recombinant, Medicaid, Growth factors, Hemoglobin, Company business planning, Banking, finance and accounting industries, Biotechnology industry
Abstract

Investor jitters eased somewhat as the Centers for Medicare & Medicaid Services' plans for reimbursement of erythropoietin (EPO) stimulating agents (ESAs) became clearer, and backers of Amgen Inc. found cause [...]

Published
2007

32. Amgen Falls Marginally; Announces Plans for Joint Development with AstraZeneca

Subjects
Amgen Inc. -- Planning, AstraZeneca PLC -- Planning, Biotechnology industry -- Planning, Monoclonal antibodies, Pharmaceutical industry -- Planning, Company business planning, Business
Abstract

Boston, Apr 02, 2012 (MidnightTrader via COMTEX) -- Amgen Inc.(AMGN) shares are down 0.33% to $67.88 in extended hours trade. The company announced a joint development and commercialization agreement with [...]

Published
2012

33. Chief of Amgen Plans to Retire

Subjects
Company business planning, Amgen Inc. -- Officials and employees, Amgen Inc. -- Planning, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Planning
Abstract

Gordon M. Binder, the chief executive of Amgen Inc., will retire after the company's annual shareholders' meeting in May and be replaced by Kevin W. Sharer, the president and chief [...]

Published
1999

34. Amgen looks to future

Subjects
Amgen Inc. -- Planning, Business plans, Biotechnology industry -- Planning, Business planning, Pharmaceutical industry -- Planning, Company business planning, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

NEW YORK -- Amgen Inc. recently outlined its business strategy and capital allocation plans and provided financial guidance for 2015. During a meeting that was held here with investors, chairman [...]

Published
2011

35. Ready to grow

Subjects
Amgen Inc. -- Planning, Amgen Inc. -- Investments, Biotechnology industry -- Planning, Biotechnology industry -- Investments, Pharmaceutical industry, Company business planning, Company investment, Business, Pharmaceuticals and cosmetics industries
Abstract

The world's largest biotechnology company is taking steps to become even bigger. In the coming year, Amgen Inc. anticipates significant investment in additional manufacturing and R&D operations in the United [...]

Published
2006

36. Amgen extends global reach

Author

Jusko, Jill

Subjects
Pharmaceutical industry -- Planning, Pharmaceutical industry -- Investments, Pharmaceutical industry -- Foreign operations, Company business planning, Company investment, Amgen Inc. -- Planning, Amgen Inc. -- Investments, Amgen Inc. -- Foreign operations
Abstract

There appears to be no slowing down biotechnology firm Amgen, whose president and chief executive officer, Kevin Sharer, was named IndustryWeek's CEO of the Year in the publication's january 2005 […]

Published
2006

37. Ireland pops $1bn Cork as US giant Amgen moves in

Subjects
Amgen Inc. -- Planning, Amgen Inc. -- Investments, Amgen Inc. -- Foreign operations, Pharmaceutical industry -- Planning, Pharmaceutical industry -- Investments, Pharmaceutical industry -- Foreign operations, Company business planning, Company investment, Business, Chemicals, plastics and rubber industries
Published
2006

38. Amgen expands R&D and manufacturing

Subjects
Amgen Inc. -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Pharmaceuticals and cosmetics industries
Abstract

The United States pharmaceutical company Amgen is expanding its manufacturing and research facilities in Ireland, United States and United Kingdom. Complete details of this 1 billion dollar expansion plans are presented.

Published
2006

39. Pfizer reportedly gives up plan to bid for Onyx

Subjects
Amgen Inc. -- Planning, Pfizer Inc. -- Planning, Bristol-Myers Squibb Co. -- Planning, Gilead Sciences Inc. -- Planning, Onyx Pharmaceuticals Inc. -- Planning, AstraZeneca PLC -- Planning, Biological products industry -- Planning, Biotechnology industry -- Planning, Health care industry -- Planning, Pharmaceutical industry -- Planning, Health care industry, Company business planning, Business, general
Abstract

MANews-(C)2009-2013 19 July 2013 - US biopharmaceutical group Pfizer Inc (NYSE:PFE) dropped plans to make a first-round bid for Onyx Pharmaceuticals Inc (NASDAQ:ONXX) this week, mainly because it considered the [...]

Published
2013

40. Pfizer reportedly gives up plan to bid for Onyx

Subjects
Amgen Inc. -- Planning, Pfizer Inc. -- Planning, Onyx Pharmaceuticals Inc. -- Planning, Biotechnology industry -- Planning, Health care industry -- Planning, Pharmaceutical industry -- Planning, Health care industry, Company business planning, Business
Abstract

M2 EQUITYBITES-July 19, 2013-Pfizer reportedly gives up plan to bid for Onyx(C)2013 M2 COMMUNICATIONS http://www.m2.com 19 July 2013 - US biopharmaceutical group Pfizer Inc (NYSE:PFE) dropped plans to make a [...]

Published
2013

41. Amgen to honor teachers for contributions, impact

Subjects
Amgen Inc. -- Services, Amgen Inc. -- Planning, Science teachers -- Achievements and awards, Pharmaceutical industry -- Services, Pharmaceutical industry -- Planning, Company business planning, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

THOUSAND OAKS, Calif. -- Amgen Inc. has called for nominations for its 14th annual Amgen Award for Science Teaching Excellence. The award honors exceptional science teachers in communities where Amgen [...]

Published
2004

42. AMGEN

Subjects
Amgen Inc. -- Mergers, acquisitions and divestments, Amgen Inc. -- Planning, Tularik Genomics -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Planning, Company business planning, Company acquisition/merger, Business, Chemicals, plastics and rubber industries
Abstract

AMGEN, the world's largest biotechnology company said it would merge with Tularik, a pioneer in gene-regulation treatment of cancer and other diseases in a US$1.3bn transaction expected to close in [...]

Published
2004

44. Amgen's R&D goals

Subjects
Amgen Inc. -- Planning, Medical research -- Planning, Business, Pharmaceuticals and cosmetics industries
Published
1994

46. Amgen Inc. will build drug plant in P.R

Author

Trinidad, Pablo J.

Subjects
Amgen Inc. -- Planning, Pharmaceutical industry -- Planning, Biotechnology industry -- Planning, Outsourcing -- Planning, Business, Business, international
Abstract

Amgen Inc. will build drug plant in P.R. California-based Amgen Inc. one of the world's leading biotechnology firms, will be establishing manufacturing operations in Puerto Rico to produce advanced pharmaceutical [...]

Published
1991

48. Amgen's GDNF misses in Phase II Parkinson's trial

Subjects
Amgen Inc. -- Planning, Amgen Inc. -- Product development, Clinical trials -- Planning, Parkinson's disease -- Drug therapy, Pharmaceutical industry -- Planning, Pharmaceutical industry -- Product development, Company business planning, Biotechnology industry
Abstract

Amgen Inc.'s therapy for Parkinson's disease failed to meet its primary endpoint in a Phase II study. The company's glial cell line-derived neurotrophic factor, also called CDNF, did not show [...]

Published
2004

49. 'Amgen's woes stall plans for $1B plant in Ireland

Subjects
Amgen Inc. -- Planning, Pharmaceutical industry -- Planning, Company business planning, Biotechnology industry
Abstract

Amgen Inc., of Thousand Oaks, Calif. has postponed 'indefinitely' plans for a $1 billion process development, bulk manufacturing and fill-and-finish plant in Ireland. The company said an 'evolving business environment' [...]

Published
2007

50. Amgen to build in Boston

Subjects
Amgen Inc. -- Planning, Biotechnology industry -- Planning, Biotechnology industry, Business
Published
1993

Catalog

Books, media, physical & digital resources
See catalog results